Effect of CD34-TRAIL⁺ cells on KMS-11 tumor growth. NOD/SCID mice bearing SC tumor nodules 10 mm in diameter were randomly assigned to the different treatment groups, including daily injections of CD34-TRAIL⁺ cells (red square) or mock-transduced CD34⁺ cells (green inverted triangle; 1 × 10⁶ cells/mouse/injection per day intravenously, days 12-15), a 4-day course of recombinant sTRAIL (blue triangle; 30 mg/kg per day intraperitoneally, days 12-15), and control vehicle (●). Arrows indicate treatment administration. Mean (± SEM) tumor weight data are shown. °P < .05, *P < .001 compared with controls.